SCHEMBL7593232

SCHEMBL7593232

CC(=O)N(C(C)=O)C(CCCCN)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 5/20 0.49
GSR P00390 1/20 0.48
RNPEP Q9H4A4 1/20 0.47
GABRR1 P24046 2/20 0.42
PAOX Q6QHF9 3/20 0.38
FOLH1 Q04609 1/20 0.38
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PLG P00747 1/20 0.34
LMNA P02545 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
SLC6A2 P23975 1/20 0.34
RECQL P46063 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7593236 1.00 CPB2 (0.49) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL8200953 0.98 CPB2 (0.51) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL4727762 0.94 GABRR1 (0.43) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL4727761 0.94 GABRR1 (0.43) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL19742925 0.94 GABRR1 (0.43) CPB2GSRRNPEPGABRR1PAOX
D-Alanine SCHEMBL4086747 0.93 GSR (0.47) CPB2GSRRNPEPGABRR1PAOX
Alanine SCHEMBL28591585 0.93 GSR (0.47) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL4902761 0.90 CPB2 (0.44) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL27731516 0.90 CPB2 (0.44) CPB2GSRRNPEPGABRR1PAOX
SCHEMBL27731517 0.90 CPB2 (0.44) CPB2GSRRNPEPGABRR1PAOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339370-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS AVANTOR PERFORMANCE MATERIALS, LLC (US) 2025-11-06 US claimed
EP-4319795-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS Avantor Performance Materials, LLC (US) 2024-02-14 EP claimed
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN claimed
WO-2022217021-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS AVANTOR PERFORMANCE MATERIALS, LLC (US) 2022-10-13 WO claimed
WO-1995003330-A1 SOMATOSTATIN DERIVATIVES AND THEIR RADIOLABELLED PRODUCTS DIATECH, INC. (US) 1995-02-02 WO claimed
WO-1995000553-A1 RADIOLABELED SOMATOSTATIN-DERIVED PEPTIDES FOR IMAGING AND THERAPEUTIC USES DIATECH, INC. (US) 1995-01-05 WO claimed
US-20250339370-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS AVANTOR PERFORMANCE MATERIALS, LLC (US) 2025-11-06 US disclosed
US-20250339370-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS AVANTOR PERFORMANCE MATERIALS, LLC (US) 2025-11-06 US disclosed
EP-4319795-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS Avantor Performance Materials, LLC (US) 2024-02-14 EP disclosed
EP-4319795-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS Avantor Performance Materials, LLC (US) 2024-02-14 EP disclosed
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN disclosed
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN disclosed
CN-115684600-A Method for acquiring quantitative proteome by eight-label independent data based on quality defect 复旦大学 2023-02-03 CN disclosed
US-8506655-B1 Fluorescent dyes containing phosphorus or arsenic ENZO LIFE SCIENCES, INC. (US) 2013-08-13 US disclosed
JP-2002087936-A NAIL COSMETIC SHIYUU UEMURA KESHOHIN:KK 2002-03-27 JP disclosed
WO-1995003330-A1 SOMATOSTATIN DERIVATIVES AND THEIR RADIOLABELLED PRODUCTS DIATECH, INC. (US) 1995-02-02 WO disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed
EP-0015771-A1 N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015773-A2 N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339370-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS AADAT, KYNU, PNISR CPB2 689/4885GSR 2191/4885RNPEP 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.